(-)-demecolcine decreases expression ISO IPO5 (Homo sapiens) 6480464 Demecolcine results in decreased expression of IPO5 mRNA CTD PMID:23649840 (1->4)-beta-D-glucan multiple interactions ISO Ipo5 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of IPO5 mRNA CTD PMID:36331819 1,2-dimethylhydrazine increases expression ISO Ipo5 (Mus musculus) 6480464 1 and 2-Dimethylhydrazine results in increased expression of IPO5 mRNA CTD PMID:22206623 1,2-dimethylhydrazine multiple interactions ISO Ipo5 (Mus musculus) 6480464 Folic Acid inhibits the reaction [1 and 2-Dimethylhydrazine results in increased expression of IPO5 mRNA] CTD PMID:22206623 17alpha-ethynylestradiol multiple interactions ISO Ipo5 (Mus musculus) 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of IPO5 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO Ipo5 (Mus musculus) 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of IPO5 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO IPO5 (Homo sapiens) 6480464 Tetrachlorodibenzodioxin results in decreased expression of IPO5 mRNA CTD PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO Ipo5 (Mus musculus) 6480464 Tetrachlorodibenzodioxin affects the expression of IPO5 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of IPO5 mRNA CTD PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO Ipo5 (Mus musculus) 6480464 Tetrachlorodibenzodioxin results in increased expression of IPO5 mRNA CTD PMID:19770486 2-amino-14,16-dimethyloctadecan-3-ol decreases expression ISO IPO5 (Homo sapiens) 6480464 2-amino-14 and 16-dimethyloctadecan-3-ol results in decreased expression of IPO5 protein CTD PMID:32044396 2-methoxyethanol increases expression EXP 6480464 methyl cellosolve results in increased expression of IPO5 mRNA CTD PMID:21061450 3,3',4,4'-tetrachlorobiphenyl multiple interactions ISO Ipo5 (Mus musculus) 6480464 3 more ... CTD PMID:19467301 3,4-methylenedioxymethamphetamine decreases expression EXP 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of IPO5 mRNA CTD PMID:30071829 4,4'-sulfonyldiphenol increases expression ISO IPO5 (Homo sapiens) 6480464 bisphenol S results in increased expression of IPO5 protein CTD PMID:34186270 acrolein multiple interactions ISO IPO5 (Homo sapiens) 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of IPO5 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of and results in increased oxidation of IPO5 mRNA CTD PMID:32699268 Aflatoxin B2 alpha increases methylation ISO IPO5 (Homo sapiens) 6480464 aflatoxin B2 results in increased methylation of IPO5 intron CTD PMID:30157460 all-trans-retinoic acid decreases expression ISO IPO5 (Homo sapiens) 6480464 Tretinoin results in decreased expression of IPO5 mRNA CTD PMID:15498508 more ... alpha-pinene multiple interactions ISO IPO5 (Homo sapiens) 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of IPO5 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of and results in increased oxidation of IPO5 mRNA CTD PMID:32699268 antimycin A increases expression ISO IPO5 (Homo sapiens) 6480464 Antimycin A results in increased expression of IPO5 mRNA CTD PMID:33512557 antirheumatic drug increases expression ISO IPO5 (Homo sapiens) 6480464 Antirheumatic Agents results in increased expression of IPO5 mRNA CTD PMID:24449571 aristolochic acid A decreases expression ISO IPO5 (Homo sapiens) 6480464 aristolochic acid I results in decreased expression of IPO5 mRNA CTD PMID:33212167 arsenite(3-) multiple interactions ISO IPO5 (Homo sapiens) 6480464 arsenite inhibits the reaction [G3BP1 protein binds to IPO5 mRNA] CTD PMID:32406909 atrazine decreases expression ISO IPO5 (Homo sapiens) 6480464 Atrazine results in decreased expression of IPO5 mRNA CTD PMID:22378314 benzo[a]pyrene increases methylation ISO IPO5 (Homo sapiens) 6480464 Benzo(a)pyrene results in increased methylation of IPO5 promoter CTD PMID:27901495 benzo[a]pyrene diol epoxide I decreases expression ISO IPO5 (Homo sapiens) 6480464 7 more ... CTD PMID:26238291 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of IPO5 mRNA CTD PMID:25181051 bisphenol A decreases expression ISO IPO5 (Homo sapiens) 6480464 bisphenol A results in decreased expression of IPO5 protein CTD PMID:37567409 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of IPO5 mRNA CTD PMID:32145629 Bisphenol B increases expression ISO IPO5 (Homo sapiens) 6480464 bisphenol B results in increased expression of IPO5 protein CTD PMID:34186270 bisphenol F increases expression ISO IPO5 (Homo sapiens) 6480464 bisphenol F results in increased expression of IPO5 protein CTD PMID:34186270 C60 fullerene decreases expression EXP 6480464 fullerene C60 results in decreased expression of IPO5 mRNA CTD PMID:19167457 calcitriol decreases expression ISO IPO5 (Homo sapiens) 6480464 Calcitriol results in decreased expression of IPO5 mRNA CTD PMID:16847355 carbamazepine affects expression ISO IPO5 (Homo sapiens) 6480464 Carbamazepine affects the expression of IPO5 mRNA CTD PMID:25979313 carbon nanotube increases expression ISO Ipo5 (Mus musculus) 6480464 Nanotubes more ... CTD PMID:25554681 chlordecone multiple interactions ISO Ipo5 (Mus musculus) 6480464 Chlordecone promotes the reaction [Biomarkers metabolite binds to IPO5 gene] CTD PMID:31084621 chlorpyrifos decreases expression ISO Ipo5 (Mus musculus) 6480464 Chlorpyrifos results in decreased expression of IPO5 mRNA CTD PMID:37019170 chromium(6+) affects expression ISO Ipo5 (Mus musculus) 6480464 chromium hexavalent ion affects the expression of IPO5 mRNA CTD PMID:28472532 clofibrate increases expression ISO Ipo5 (Mus musculus) 6480464 Clofibrate results in increased expression of IPO5 mRNA CTD PMID:17585979 cobalt dichloride decreases expression ISO IPO5 (Homo sapiens) 6480464 cobaltous chloride results in decreased expression of IPO5 mRNA CTD PMID:19320972 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of IPO5 mRNA CTD PMID:24386269 coumarin affects phosphorylation ISO IPO5 (Homo sapiens) 6480464 coumarin affects the phosphorylation of IPO5 protein CTD PMID:35688186 decabromodiphenyl ether decreases expression EXP 6480464 decabromobiphenyl ether results in decreased expression of IPO5 mRNA CTD PMID:23640034 deguelin increases expression ISO IPO5 (Homo sapiens) 6480464 deguelin results in increased expression of IPO5 mRNA CTD PMID:33512557 dicrotophos decreases expression ISO IPO5 (Homo sapiens) 6480464 dicrotophos results in decreased expression of IPO5 mRNA CTD PMID:28302478 dioxygen multiple interactions ISO Ipo5 (Mus musculus) 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of IPO5 mRNA CTD PMID:30529165 dorsomorphin multiple interactions ISO IPO5 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO IPO5 (Homo sapiens) 6480464 Doxorubicin results in decreased expression of IPO5 mRNA CTD PMID:29803840 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of IPO5 mRNA CTD PMID:29391264 enzyme inhibitor multiple interactions ISO IPO5 (Homo sapiens) 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of IPO5 protein CTD PMID:23301498 ethanol affects splicing ISO Ipo5 (Mus musculus) 6480464 Ethanol affects the splicing of IPO5 mRNA CTD PMID:30319688 fenpyroximate increases expression ISO IPO5 (Homo sapiens) 6480464 fenpyroximate results in increased expression of IPO5 mRNA CTD PMID:33512557 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of IPO5 mRNA CTD PMID:30307764 fipronil increases expression EXP 6480464 fipronil results in increased expression of IPO5 mRNA CTD PMID:34044035 flutamide increases expression EXP 6480464 Flutamide results in increased expression of IPO5 mRNA CTD PMID:24136188 folic acid multiple interactions ISO Ipo5 (Mus musculus) 6480464 Folic Acid inhibits the reaction [1 and 2-Dimethylhydrazine results in increased expression of IPO5 mRNA] CTD PMID:22206623 formaldehyde decreases expression ISO IPO5 (Homo sapiens) 6480464 Formaldehyde results in decreased expression of IPO5 mRNA CTD PMID:23649840 FR900359 increases phosphorylation ISO IPO5 (Homo sapiens) 6480464 FR900359 results in increased phosphorylation of IPO5 protein CTD PMID:37730182 fulvestrant increases methylation ISO IPO5 (Homo sapiens) 6480464 Fulvestrant results in increased methylation of IPO5 gene CTD PMID:31601247 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of IPO5 mRNA CTD PMID:33387578 hydrogen peroxide affects expression ISO IPO5 (Homo sapiens) 6480464 Hydrogen Peroxide affects the expression of IPO5 mRNA CTD PMID:20044591 indometacin decreases expression ISO IPO5 (Homo sapiens) 6480464 Indomethacin results in decreased expression of IPO5 mRNA CTD PMID:16984733 inulin multiple interactions ISO Ipo5 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of IPO5 mRNA CTD PMID:36331819 ivermectin decreases expression ISO IPO5 (Homo sapiens) 6480464 Ivermectin results in decreased expression of IPO5 protein CTD PMID:32959892 ketoconazole decreases expression ISO IPO5 (Homo sapiens) 6480464 Ketoconazole results in decreased expression of IPO5 mRNA CTD PMID:36621641 lovastatin decreases expression ISO Ipo5 (Mus musculus) 6480464 Lovastatin results in decreased expression of IPO5 mRNA CTD PMID:20493250 mercury dichloride increases expression EXP 6480464 Mercuric Chloride results in increased expression of IPO5 mRNA CTD PMID:16507785 methyl methanesulfonate decreases expression ISO IPO5 (Homo sapiens) 6480464 Methyl Methanesulfonate results in decreased expression of IPO5 mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO IPO5 (Homo sapiens) 6480464 methylmercuric chloride results in decreased expression of IPO5 mRNA CTD PMID:28001369 miconazole increases expression ISO Ipo5 (Mus musculus) 6480464 Miconazole results in increased expression of IPO5 mRNA CTD PMID:27462272 nefazodone increases expression EXP 6480464 nefazodone results in increased expression of IPO5 mRNA CTD PMID:24136188 nimesulide increases expression EXP 6480464 nimesulide results in increased expression of IPO5 mRNA CTD PMID:24136188 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of IPO5 mRNA CTD PMID:25729387 ozone multiple interactions ISO IPO5 (Homo sapiens) 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of IPO5 mRNA more ... CTD PMID:32699268 paracetamol affects expression ISO Ipo5 (Mus musculus) 6480464 Acetaminophen affects the expression of IPO5 mRNA CTD PMID:17562736 paracetamol decreases expression ISO IPO5 (Homo sapiens) 6480464 Acetaminophen results in decreased expression of IPO5 mRNA CTD PMID:21420995 paraquat increases expression EXP 6480464 Paraquat results in increased expression of IPO5 mRNA CTD PMID:32680482 perfluorohexanesulfonic acid increases expression ISO Ipo5 (Mus musculus) 6480464 perfluorohexanesulfonic acid results in increased expression of IPO5 mRNA CTD PMID:37995155 perfluorooctane-1-sulfonic acid multiple interactions ISO Ipo5 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of IPO5 mRNA and [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of IPO5 mRNA CTD PMID:36331819 phenylmercury acetate decreases expression ISO IPO5 (Homo sapiens) 6480464 Phenylmercuric Acetate results in decreased expression of IPO5 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO IPO5 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO5 mRNA CTD PMID:27188386 picoxystrobin increases expression ISO IPO5 (Homo sapiens) 6480464 picoxystrobin results in increased expression of IPO5 mRNA CTD PMID:33512557 pirinixic acid increases expression ISO Ipo5 (Mus musculus) 6480464 pirinixic acid results in increased expression of IPO5 mRNA CTD PMID:18301758 SB 431542 multiple interactions ISO IPO5 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide affects secretion ISO IPO5 (Homo sapiens) 6480464 Silicon Dioxide analog affects the secretion of IPO5 protein CTD PMID:25895662 sodium fluoride increases expression ISO Ipo5 (Mus musculus) 6480464 Sodium Fluoride results in increased expression of IPO5 protein CTD PMID:28918527 sunitinib increases expression ISO IPO5 (Homo sapiens) 6480464 Sunitinib results in increased expression of IPO5 mRNA CTD PMID:31533062 tamibarotene affects expression ISO IPO5 (Homo sapiens) 6480464 tamibarotene affects the expression of IPO5 mRNA CTD PMID:15498508 tebufenpyrad increases expression ISO IPO5 (Homo sapiens) 6480464 4-chloro-N-((4-(1 and 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of IPO5 mRNA CTD PMID:33512557 tetrachloroethene increases expression ISO Ipo5 (Mus musculus) 6480464 Tetrachloroethylene results in increased expression of IPO5 mRNA CTD PMID:28973375 tetrachloromethane increases expression ISO Ipo5 (Mus musculus) 6480464 Carbon Tetrachloride results in increased expression of IPO5 mRNA CTD PMID:27339419 and PMID:31919559 thapsigargin increases expression ISO Ipo5 (Mus musculus) 6480464 Thapsigargin results in increased expression of IPO5 protein CTD PMID:24648495 thifluzamide increases expression ISO IPO5 (Homo sapiens) 6480464 thifluzamide results in increased expression of IPO5 mRNA CTD PMID:33512557 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of IPO5 mRNA CTD PMID:23411599 and PMID:34492290 titanium dioxide increases expression ISO Ipo5 (Mus musculus) 6480464 titanium dioxide results in increased expression of IPO5 mRNA CTD PMID:23557971 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of IPO5 mRNA CTD PMID:25729387 trichostatin A decreases expression ISO IPO5 (Homo sapiens) 6480464 trichostatin A results in decreased expression of IPO5 mRNA CTD PMID:24935251 and PMID:26272509 trichostatin A multiple interactions ISO IPO5 (Homo sapiens) 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO5 mRNA CTD PMID:27188386 trimellitic anhydride increases expression ISO Ipo5 (Mus musculus) 6480464 trimellitic anhydride results in increased expression of IPO5 mRNA CTD PMID:19042947 valproic acid increases methylation ISO IPO5 (Homo sapiens) 6480464 Valproic Acid results in increased methylation of IPO5 gene CTD PMID:29154799 valproic acid decreases expression ISO IPO5 (Homo sapiens) 6480464 Valproic Acid results in decreased expression of IPO5 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO IPO5 (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPO5 mRNA CTD PMID:27188386 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of IPO5 mRNA CTD PMID:20566332 vinclozolin decreases methylation EXP 6480464 vinclozolin results in decreased methylation of IPO5 gene CTD PMID:31079544 vincristine decreases expression ISO IPO5 (Homo sapiens) 6480464 Vincristine results in decreased expression of IPO5 mRNA CTD PMID:23649840 warfarin decreases expression ISO Ipo5 (Mus musculus) 6480464 Warfarin results in decreased expression of IPO5 mRNA CTD PMID:20493250